• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Theravance/Glaxo's Breo Ellipta wins FDA go-ahead

May 15, 2013 By drugdelivery

Theravance/Glaxo's Breo Ellipta wins FDA go-ahead

GlaxoSmithKline (NYSE:GSK) and Theravance (NSDQ:THRX) won FDA approval for their co-developed Breo Ellipta inhaler for treatment of airflow obstructions, including bronchitis and emphysema in patients with chronic obstructive pulmonary disease.

The once daily, long-term maintenance inhaler is also indicated to reduce COPD exacerbations in patients with a history of such flare-ups, the companies said.

Breo Ellipta is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist vilanterol and is delivered to the patient using Theravance’s Ellipta, a new dry powder inhaler.

"The FDA approval of Breo Elipta brings an important inhaled, once-daily maintenance therapeutic option to COPD patients and doctors across the United States," Theravance CEO Rick Winningham said in a press statement. "After more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK."

Theravance and GlaxoSmithKline anticipate rolling out Breo Ellipta in the U.S. during the third quarter of fiscal 2013. Under previously set terms, FDA approval of Breo Ellipta obligates Theravance to make a milestone payment of $30 million to GSK.

The National Heart, Lung and Blood Institute estimates that as many as 27 million people in the US alone are affected by COPD, a number that is predicted to increase, the companies pointed out.

"This approval means that we can now realize our plan to bring Breo Ellipta to appropriate COPD patients in the U.S.," head of GSK Global Respiratory Franchise Darrell Baker said in a press statement. "We know that one of the main issues for patients who have experienced a COPD exacerbation is concern about possible future episodes. Breo Ellipta will help patients breathe better day-to-day and reduce the risk of future exacerbations, with a once-daily inhalation."

GlaxoSmithKline and Theravance are also seeking regulatory approval of the inhaler, under the trade name Relvar Ellipta, in Europe and Japan, the companies said.

Filed Under: Drug-Device Combinations Tagged With: GlaxoSmithKline plc, Pulmonary, Theravance

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS